Skip to main content Accessibility help

Progress and Challenges in Implementing the Research on ESKAPE Pathogens

  • Louis B. Rice (a1)


The ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) are responsible for a substantial percentage of nosocomial infections in the modern hospital and represent the vast majority of isolates whose resistance to antimicrobial agents presents serious therapeutic dilemmas for physicians. Over the years, improved molecular biology techniques have led to detailed information about individual resistance mechanisms in all these pathogens. However, there remains a lack of compelling data on the interplay between resistance mechanisms and between the bacteria themselves. In addition, data on the impact of clinical interventions to decrease the prevalence of resistance are also lacking. The difficulty in identifying novel antimicrobial agents with reliable activity against these pathogens argues for an augmentation of research in the basic and population science of resistance, as well as careful studies to identify optimal strategies for infection control and antimicrobial use.


Corresponding author

Medical Service 111(W), Louis Stokes Cleveland VA Medical Center, 10701 East Boulevard, Cleveland, OH 44106 (


Hide All
1.Pronovost, P, Needham, D, Berenholtz, S, et al.An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 2006;355(26):27252732.
2.Rice, LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008;197(8):10791081.
3.Hidron, AI, Edwards, JR, Patel, J, et al.NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infect Control Hosp Epidemiol 2008;29(11):9961011.
4.European Antimicrobial Resistance Surveillance System (EARSS). EARSS annual report 2007. Bilthoven, the Netherlands: EARSS; 2008. Accessed 1 July 2010.
5.Arthur, M, Molinas, C, Depardieu, F, Courvalin, P. Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J Bacteriol 1993;175(1):117127.
6.Carias, LL, Rudin, SD, Donskey, CJ, Rice, LB. Genetic linkage and cotransfer of a novel, vonB-containing transposon (Tn5382) and a low-affinity penicillin-binding protein 5 gene in a clinical vancomycin-resistant Enterococcus faecium isolate. J Bacteriol 1998;180(17):44264434.
7.Rice, LB, Bellais, S, Carias, LL, et al.Impact of specific pbp5 mutations on expression of β-lactam resistance in Enterococcus faecium. Antimicrob Agents Chemother 2004;48(8):30283032.
8.Fuda, CC, Fisher, JF, Mobashery, S. β-Lactam resistance in Staphylococcus aureus: the adaptive resistance of a plastic genome. Cell Mol Life Sci 2005;62(22):26172633.
9.Jacoby, GA, Medeiros, AA. More extended-spectrum β-lactamases. Antimicrob Agents Chemother 1991;35(9):16971704.
10.Schiappa, DA, Hayden, MK, Matushek, MG, et al.Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. J Infect Dis 1996;174(3):529536.
11.Pitout, JD. Multiresistant Enterobacteriaceae: new threat of an old problem. Expert Rev Anti Infect Ther 2008;6(5):657669.
12.Rice, LB, Carias, LL, Hutton, RA, Rudin, SD, Endimiani, A, Bonomo, RA. The KQ element, a complex genetic region conferring transferable resistance to carbapenems, aminoglycosides, and fluoroquinolones in Klebsiella pneumoniae. Antimicrob Agents Chemother 2008;52(9):34273429.
13.Peleg, AY, Seifert, H, Paterson, DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008;21(3):538582.
14.Nikaido, H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev 2003;67(4):593656.
15.Fournier, PE, Vallenet, D, Barbe, V, et al.Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet 2006;2(1):e7.
16.Whitecar, JP JrLuna, M, Bodey, GP. Pseudomonas bacteremia in patients with malignant diseases. Am J Med Sci 1970;60(4):216223.
17.Livermore, DM. Interplay of impermeability and chromosomal β-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 1992;36(9):20462048.
18.Tam, VH, Chang, KT, Abdelraouf, K, et al.Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010;54:11601164.
19.Jacobs, C, Frere, J-M, Normark, S. Cytosolic intermediates for cell wall biosynthesis and degradation control inducible β-lactam resistance in gram-negative bacteria. Cell 1997;88(6):823832.
20.Jacobs, C, Huang, LJ, Bartowsky, E, Normark, S, Park, JT. Bacterial cell wall recycling provides cytosolic muropeptides as effectors for β-lactamase induction. EMBO J 1994;13(19):46844694.
21.Jacobs, C, Joris, B, Jamin, M, et al.AmpD, essential for both β-lactamase regulation and cell wall recycling, is a novel cytosolic N-acetylmuramyl-L-alanine amidase. Mol Microbiol 1995;15(3):553559.
22.Sanders, CC, Sanders, WE JrGoering, RV. In vitro antagonism of β-lactam antibiotics by cefoxitin. Antimicrob Agents Chemother 1982;21:968975.
23.Schmidtke, AJ, Hanson, ND. Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008;52(11):39223927.
24.Chambers, HF. Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin Microbiol Rev 1997;10(4):781791.
25.Rice, LB, Carias, LL, Rudin, S, et al.Role of class A penicillin-binding proteins in the expression of β-lactam resistance in Enterococcus faecium. J Bacteriol 2009;191(11):36493656.
26.Strahilevitz, J, Jacoby, GA, Hooper, DC, Robicsek, A. Plasmid-mediated quinolone resistance: a multifaceted threat. Clin Microbiol Rev 2009;22(4):664689.
27.Hernandez-Alles, S, Alberti, S, Alvarez, D, et al.Porin expression in clinical isolates of Klebsiella pneumoniae. Microbiology 1999;145(3):673679.
28.Lewis, K. Multidrug tolerance of biofilms and persister cells. Curr Top Microbiol Immunol 2008;322:107131.
29.Brook, I. The role of beta-lactamase-producing-bacteria in mixed infections. BMC Infect Dis 2009;9:202.
30.Yim, G, Wang, HH, Davies, J. Antibiotics as signalling molecules. Philos Trans R Soc Lond B Biol Sci 2007;362(1483):11951200.
31.Projan, SJ, Shlaes, DM. Antibacterial drug discovery: is it all downhill from here? Clin Microbiol Infect 2004;10(Suppl 4):1822.
32.Boucher, HW, Talbot, GH, Bradley, JS, et al.Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48(1):112.


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed